Preliminary reports from several groups indicate that a subset of adult patients with idiopathic PAP respond favorably to GM-CSF therapy.1 Epidemiological data is scarce but one estimate suggests an annual incidence of the order of 2 to 5 per million. Here, CSF2 is linked to pulmonary alveolar proteinosis.